Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 539.6 g/mol |
---|---|
Molecular Formula | C31H33N5O4 |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 539.25325455 g/mol |
Monoisotopic Mass | 539.25325455 g/mol |
Topological Polar Surface Area | 94.2 A^2 |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 947 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Ofev |
Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
Active Ingredient | Nintedanib |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
2 of 2 | |
---|---|
Drug Name | Ofev |
Drug Label | OFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin... |
Active Ingredient | Nintedanib |
Dosage Form | Capsule |
Route | Oral |
Strength | 150mg; 100mg |
Market Status | Prescription |
Company | Boehringer Ingelheim |
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-26
Pay. Date : 2018-12-20
DMF Number : 33361
Submission : 2019-01-02
Status : Active
Type : II
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2022-01-12
Registration Number : 163-23-ND
Manufacturer Name : Fermion Oy
Manufacturer Address : Lääketehtaantie 2, Oulu, FI-90660, Finland
Available Reg Filing : ASMF |
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-04-27
Pay. Date : 2018-03-30
DMF Number : 32511
Submission : 2018-03-29
Status : Active
Type : II
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-03
Pay. Date : 2018-09-20
DMF Number : 33152
Submission : 2018-09-28
Status : Active
Type : II
NDC Package Code : 82758-505
Start Marketing Date : 2022-05-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-05-08
Pay. Date : 2023-03-28
DMF Number : 37986
Submission : 2023-03-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-05
Pay. Date : 2019-10-10
DMF Number : 32152
Submission : 2017-12-28
Status : Active
Type : II
Date of Issue : 2023-12-28
Valid Till : 2026-12-28
Written Confirmation Number : WC-0310
Address of the Firm :
GDUFA
DMF Review : Complete
Rev. Date : 2019-03-26
Pay. Date : 2018-12-20
DMF Number : 33361
Submission : 2019-01-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-04-27
Pay. Date : 2018-03-30
DMF Number : 32511
Submission : 2018-03-29
Status : Active
Type : II
Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.
GDUFA
DMF Review : Complete
Rev. Date : 2018-12-03
Pay. Date : 2018-09-20
DMF Number : 33152
Submission : 2018-09-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-06-05
Pay. Date : 2018-03-19
DMF Number : 32504
Submission : 2018-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-07-09
Pay. Date : 2018-04-24
DMF Number : 32643
Submission : 2018-04-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32408
Submission : 2018-01-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-11-05
Pay. Date : 2019-10-10
DMF Number : 32152
Submission : 2017-12-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-24
Pay. Date : 2019-12-02
DMF Number : 34332
Submission : 2019-12-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-09-05
Pay. Date : 2018-03-07
DMF Number : 31526
Submission : 2017-03-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32529
Submission : 2018-02-22
Status : Active
Type : II
About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
About the Company : Midas Pharma is a pharmaceutical company that excels in providing extensive expertise while fostering connections between companies, individuals, and knowledge. The core competence...
About the Company : Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the...
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
About the Company : Established in 1990, Inabata France, a part of the Inabata Group, used to export chemical and pharmaceutical products to Japan. In 2006, it acquired Pharmasynthèse. Today, Inabata...
Hubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.
About the Company : Hubei Gedian Humanwell Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical company with a focus on the research and development, production, and sales of fertility regula...
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...
About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrosis
Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : MNKD-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2024
Details:
AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avalyn Initiates Phase 1b Study for AP02, Novel Inhaled Nintedanib
Details : AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : AP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2024
Details:
The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MannKind Proceeds with Phase 1 Nintedanib Dpi Study for Pulmonary Fibrotic Diseases
Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Brand Name : MNKD-201
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Accepts Supplemental New Drug Application for OFEV® (nintedanib) for Children and Adoles...
Details : OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2023
Details:
AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fibroblast activity.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fib...
Brand Name : AP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2023
Details:
The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2022
Details:
No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLD-0409
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Lead Product(s) : Cudetaxestat,Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Brand Name : BLD-0409
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2022
Details:
In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Immunology Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2021
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2021
Details:
OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: OFEV
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.
Brand Name : OFEV
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2021
Details:
New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient population.
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Icahn School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Icahn School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient ...
Brand Name : Ofev
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2020
methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxo...
CAS Number : 1168152-07-5
End Use API : Nintedanib Esylate
About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...
N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-...
CAS Number : 262368-30-9
End Use API : Nintedanib Esylate
About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...
Methyl-1-(Chloro Acetyl)-2- Oxoindoline-6-Carboxyl...
CAS Number : CAS-1160293-25-3
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
CAS Number : CAS-14192-26-8
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
1,3-Dimethyl 2-[4- (Methoxycarbonyl)-2- Nitropheny...
CAS Number : CAS-1160293-27-5
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
(Z)-Methyl 1-(2-Chloroacetyl)- 3- (Methoxy (Phenyl...
CAS Number : CAS-1160293-24-2
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
Methyl 3-[Methoxy (Phenyl)Methylene]-2- Oxoindolin...
CAS Number : CAS-1160293-22-0
End Use API : Nintedanib Esylate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
Methyl 2-Oxindoline -6-carboxylate
CAS Number : 14192-26-8
End Use API : Nintedanib Esylate
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
2-Chloro N-methyl N-(4-nitro-phenyl)acetamide
CAS Number : 2653-16-9
End Use API : Nintedanib Esylate
About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...
Methyl 2-oxindole-6-carboxylate
CAS Number : 14192-26-8
End Use API : Nintedanib Esylate
About The Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 ye...
Global Sales Information
Market Place
Reply
03 May 2023
Reply
02 Dec 2021
Reply
26 Feb 2020
Reply
17 Jun 2016
Patents & EXCLUSIVITIES
Patent Expiration Date : 2029-06-07
US Patent Number : 9907756
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-06-07
Patent Expiration Date : 2026-07-08
US Patent Number : 10154990*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-07-08
Patent Expiration Date : 2026-01-08
US Patent Number : 10154990
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code : U-2620
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-08
Patent Expiration Date : 2026-07-08
US Patent Number : 10154990*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-07-08
Patent Expiration Date : 2026-01-08
US Patent Number : 10154990
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code : U-2620
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-08
Patent Expiration Date : 2029-12-04
US Patent Number : 10105323*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-04
Patent Expiration Date : 2029-12-04
US Patent Number : 10105323*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-04
Patent Expiration Date : 2029-12-07
US Patent Number : 9907756*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-07
Patent Expiration Date : 2029-12-07
US Patent Number : 9907756*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-12-07
Patent Expiration Date : 2026-04-01
US Patent Number : 6762180*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 205832
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-04-01
REF. STANDARDS & IMPURITIES
CAS Number : 1160293-27-5
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : N0083.02
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?